← Back

Shanghai ZJ Bio-Tech Co. Ltd. A

Shanghai ZJ Bio-Tech Co., Ltd. researches, develops, produces, and sells molecular diagnostic reagents and instruments in China and internationally. Its offerings include nucleic acid and real-time PCR kits, along with consumables. The company serves the public health safety and clinical diagnostics sectors. Founded in 2005, it is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 688317.CG
688317.CG▼

Zhejiang Bio's 2026 interim net loss widens to 40.5894 million yuan

Zhejiang Bio released its 2026 interim report. Total operating revenue was 53.3882 million yuan, down 10.55% year on year. Net profit attributable to the parent company was negative 40.5894 million yuan, a decrease of 30.7384 million yuan compared with the same period last year, with the loss widening. Net cash inflow from operating activities was 11.6042 million yuan, down 55.06% year on year. The company's asset-liability ratio was 10.82%, gross margin was 65.05%, return on equity was negative 1.24%, and diluted earnings per share was negative 0.23 yuan. The number of shareholders was 14,000, and the top ten shareholders held 42.87% of the total share capital.
688317.CG ▼
Jiemian·22dRead more →
688317.CG▲3

ZJ Bio-Tech obtains Class III medical device registration certificate for monkeypox virus nucleic acid detection kit

ZJ Bio-Tech announced that its monkeypox virus nucleic acid detection kit, using fluorescent PCR method, has obtained a national Class III medical device registration certificate, valid from August 17, 2026 to August 16, 2031. The product is mainly used for in vitro qualitative detection of monkeypox virus nucleic acid in skin lesion samples from suspected monkeypox cases. In the first quarter of 2026, ZJ Bio-Tech achieved revenue of 25.42 million yuan and a net loss attributable to the parent company of 25.51 million yuan.
688317.CG ▲
财中社·30dRead more →
688317.CG

Zhejiang Bio has repurchased 4.37 million shares for a total of 85.92 million yuan

Zhejiang Bio announced that as of July 31, 2026, the company had repurchased a total of 4.37 million shares, representing 2.30% of its total share capital, for a total amount of 85.92 million yuan, at prices ranging from 14.71 yuan to 23.49 yuan per share. In the first quarter of 2026, the company achieved operating revenue of 25.42 million yuan, with a net loss attributable to shareholders of the parent company of 25.51 million yuan.
688317.CG
财中社·46dRead more →
688317.CG▲2

ZJ Bio-Tech HPV Nucleic Acid Test Product Receives National Class III Medical Device Registration Certificate

ZJ Bio-Tech announced that its product, the Human Papillomavirus 23-Type Nucleic Acid Genotyping Detection Kit (Fluorescent PCR Method), has recently obtained a National Class III Medical Device Registration Certificate, valid until July 28, 2031. The product is used for in vitro qualitative detection and genotype identification of 23 HPV types in female cervical exfoliated cell samples, covering mainstream high-risk and low-risk types. This certification will enrich the company's product portfolio, enhance its molecular diagnostics product matrix, and strengthen its market competitiveness in the HPV testing field.
688317.CG ▲
CLS·50dRead more →
688317.CG▲

ZJ Bio-Tech's Two Products Receive Certification from Vietnam's Ministry of Health

ZJ Bio-Tech announced that two of its products have recently received certification from Vietnam's Ministry of Health. After obtaining the certification, the relevant products can be sold in Vietnam and countries that recognize Vietnam's certification, which will help enhance the company's international competitiveness, expand its overseas product categories, and grow its international business. In the first quarter of 2026, ZJ Bio-Tech achieved revenue of 25.42 million yuan, with a net loss attributable to the parent company of 25.51 million yuan.
688317.CG ▲
财中社·61dRead more →
© 2026 MarketDXAsset